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The eﬃcacy of extracts and essential oils from Allium tuberosum, Coriandrum sativum, Cymbopogon martini, Cymbopogon
winterianus, and Santolina chamaecyparissus was evaluated against Candida spp. isolates from the oral cavity of patients with
periodontal disease. The most active oil was fractionated and tested against C. albicans bioﬁlm formation. The oils were obtained
bywater-distillationandtheextractswerepreparedwithmacerateddriedplantmaterial.TheMinimalInhibitoryConcentration—
MIC was determined by the microdilution method. Chemical characterization of oil constituents was performed using Gas
Chromatography and Mass Spectrometry (GC-MS). C. sativum activity oil upon cell and bioﬁlm morphology was evaluated by
Scanning Electron Microscopy (SEM). The best activities against planktonic Candida spp. were observed for the essential oil and
the grouped F8–10 fractions from C. sativum. The crude oil also aﬀected the bioﬁlm formation in C. albicans causing a decrease in
the bioﬁlm growth. Chemical analysis of the F8–10 fractions detected as major active compounds, 2-hexen-1-ol, 3-hexen-1-ol and
cyclodecane. Standards of these compounds tested grouped provided a stronger activity than the oil suggesting a synergistic action
from the major oil constituents. The activity of C. sativum oil demonstrates its potential for a new natural antifungal formulation.
1.Introduction
During the last two decades, the yeasts of the genus Can-
dida have received notable attention in medical literature.
Colombo and Guimar˜ aes [1] emphasized the increase of
nosocomial infections caused by Candida spp. In the begin-
ning of the 80s, Candida spp. were the seventh most frequent
pathogen associated with hospital-acquired infections in the
United States of America. At the end of the 80s, this agent
represented the ﬁfth most frequent pathogen and presently,
according to the author, accounts for 8% of the cases of
hospital-acquired infections and is considered the fourth
main isolated pathogen present in diagnostic tests.
The frequency of commensal Candida species isolated in
the oral cavity of clinically healthy individuals varies from
40 to 60% [2]. Several factors predispose to the development
of candidiasis, such as endocrine disorders, pregnancy,
iron deﬁciency, immune disorders, and xerostomy [3]. The
occurrence of oral candidosis can be related to the host
and to the yeast itself. The most cited causes related to
the host are diabetes mellitus (DM), loss of teeth, changes
in dietary habits, oral hygiene, systemic diseases, hormonal
changes, immunosuppression, radiation, and chemotherapy
[4]. Among the factors related to the yeast (also called
virulence factors), adhesion phenomenon, mycelium for-
mation, phenotypic variability, production of extracellular
enzymes (protease and phospholipase), and toxins [4–6]c a n
beobserved.Furthermore,thehabilityoftheCandidaspecies
to grow as a bioﬁlm can increase the resistance to drugs,
blocking or preventing the access of antifungals to the more
internal bioﬁlm structure [7].
Candidosis is considered the most common fungal
infection of the human oral cavity, and C. albicans is the
main species related although nonalbicans species such as
C. tropicalis, C. parapsilosis, C. krusei, C. glabrata,a n dC.
dubliniensis, are becoming common among certain groups
of patients [3, 8–10]. The occurrence of severe periodontitis
has also been associated with the isolation of species of2 Evidence-Based Complementary and Alternative Medicine
Candida spp. from periodontal lesions [11–14]. The yeast,
through the access to tissues, produces metabolites that lead
to inﬂammation.
Thewidespreaduseofazoleantifungalsforthetreatment
of oral candidosis, especially after the AIDS era, seems to
have been the predominant factor for the increase in
frequency of non-Candida albicans species, especially those
naturally more resistant to this class of antifungal agents,
such as C. glabrata and C. krusei [15]. Data from some
studies suggest that prolonged or intermittent treatment
with antifungal agents modiﬁes C. albicans prevalence,
increasing the frequency of other Candida species [16, 17].
The resistance of human pathogens to multiple drugs
is well known today and indicates the need to search for
antimicrobial substances from new sources, including plants
used in folk medicine, which present a great variety of
compounds with therapeutic properties. The use of plants as
a source of drugs is prevalent in developing countries as an
alternative to health problems and is well established in some
culturesandtraditions,especiallyinAsia,LatinAmerica,and
Africa [18]. Many native plants in these regions have not yet
been studied and can be researched for antimicrobial action,
in contrast to European native plants that have already been
exhaustively studied [19]. According to Duarte & Figueira
[19], the information available on medicinal plants active
against C. albicans has not, until recently, resulted in eﬀective
formulations for human or animal use, except for some
patents concerning material derived from the plant families
Allium [20], Radix gentianae [21], and ﬁve extracts studied
by Lee et al. [22].
In Brazil, despite the existing rich ﬂora and biodiversity,
data from only approximately 44 species and 22 families with
positive activities are available, including native and exotic
plants [19]. The aim of this study was to evaluate the antimi-
crobial activity of extracts, essential oils, and fractions from
medicinal plants belonging to the CPMA-Medicinal and
Aromatic Plant Collection at CPQBA/UNICAMP, against
planktonic cells of Candida spp. from CBS collection and
isolates from patients with periodontal disease. The most
active oil, from Coriandrum sativum L, was tested against C.
albicans bioﬁlm formation.
2.MaterialsandMethods
2.1. Samples. For the development of this research,
Candida spp. reference strains obtained from Netherlands
Collection—CBS (C. albicans CBS 562, C. dubliniensis
CBS 7987, C. krusei CBS 573, C. tropicalis CBS 94, and C.
parapsilosis CBS 604) and clinical isolates from volunteers
of the Dentistry Faculty of Piracicaba-FOP/UNICAMP, S˜ ao
Paulo-Brazil as C. albicans (3A5, 13A5, 41M2, and 50M2),
C. dubliniensis 26A2, 26A3, and 26A4), C. krusei (56M3,
56M4, and 56M5), C. tropicalis (53M6, 52M7, and 53M8),
and C. parapsilosis (45M2, 45M4, and 45M5) were used.
The isolates were collected from oral mucosa and were
identiﬁed on chromogenic medium CHROMagar-Candida
and by morphological and biochemical tests. The codes
of the clinical isolates correspond to the number of the
volunteers and the place of origin (A from periodontal
pocket and M from mucosa). Subsequently, the yeasts were
stored at −70◦C in YPD medium with 15% glycerol and
maintained at the mycology collection of the Department
of Microbiology and Immunology from FOP/UNICAMP.
This research was performed under the authorization of the
Research Ethics Committee (008/2003).
2.2. Medicinal Plants. The plants studied as Allium tubero-
sum Rottl. ex Spreng, Coriandrum sativum L, Cymbopogon
martinii (Roxb.) J. F. Watson, C. winterianus Jowitt, and
Santolina chamaecyparissus were grown in the experimental
ﬁeld of the Research Center for Chemistry, Biology and
Agriculture (CPQBA), University of Campinas, S˜ ao Paulo,
Brazil. The plants were collected from November 2001
to November 2002, during the morning after dewpoint.
Voucher specimens were deposited at the University of
Campinas Herbarium (UEC) and identiﬁed by Dr. Washing-
ton Marcondes Ferreira Neto (curator), or at the herbarium
at the CPQBA.
2.3. Essential Oil Extraction. The essential oils were obtained
from 100g of aerial fresh plant parts by water distillation
using a Clevenger-type system for 3h. The aqueous phase
was extracted three times with 50mL of dichloromethane.
The pooled organic phases were dried with sodium sulphate
and ﬁltered, and the solvent was evaporated until dryness.
Oil samples were stored at −25◦C in sealed glass vials [23].
2.4. Extracts Preparation. Dried plant material (10g) was
macerated with 150mL of hexane or dichloromethane, as
indicated,andsubmittedtoshakingat200rpmatroomtem-
perature for 3h. Subsequently, the extracts were ﬁltered, and
the plant residues were re-extracted with fresh 70% ethanol.
The pooled ﬁltrates were concentrated under vacuum and
stored at 4◦C until further use [23].
2.5. Essential Oil Fractionation. The essential oil that pre-
sented best activity was fractioned in a dry column prepared
with silica gel 60 Merck (0,063–0,200mm). A cellulose bag
(3cm diameter) was used for support. The essential oil was
put directly into the packed column and eluted. The mobile
phase utilized in each column was deﬁned after essential oil
analysis using TLC (thin layer chromatography), in diﬀerent
eluents. After elution, the column was fractioned into three
parts, and the fractions were transferred individually to the
appropriatevials,solubilizedinethylacetate,andanalyzedby
TLC. Similar fractions were grouped and ﬁltered using vac-
uum and the silica residues extracted with ethyl acetate [23].
2.6. Activity Assay-Minimal Inhibitory Concentration (MIC)
Test. Yeasts were grown overnight at 36◦Ci nS a b o u r a u d
Dextrose Agar (Merck) plates. Inocula for the assays were
prepared by diluting scraped cell mass into 0.85% NaCl
solution, adjusted to McFarland scale 0.5, and conﬁrmed
by spectrophotometric reading at 580nm. Cell suspensions
wereﬁnallydilutedto104 UFCmL−1 inRPMI-1640medium
(Difco) for assays. MIC tests were carried out according
to CLSI [24], using tissue culture test plate (96wells),
containing 100μL RPMI-1640 medium. The stock solutionsEvidence-Based Complementary and Alternative Medicine 3
of the essential oil or crude extracts obtained from medicinal
plants were diluted and transferred into the ﬁrst well, and
serial dilutions were performed to obtain concentrations
ranging from 1 to 0.03mgmL−1. Nystatin and Fluconazol
(Merck) were used as antimycotic control reference ranging
from 1 to 0.03mgmL−1. The yeast inoculum was added to
all wells, and plates were incubated at 36◦C for 48h. MIC
was deﬁned as the lowest concentration of oil or extract
that inhibited visible growth, as indicated by the RPMI-1640
medium color change (pink to yellow).
2.7. C. albicans Bioﬁlm Induction. Standardized C. albicans
cells (1.0 × 106 cells/mL in RPMI 1640 medium) were
introduced into wells of 96 well tissue culture plates (TPP)
containing RPMI-1640 medium with 2% sucrose and were
incubated for 1.5h at 37◦C. After the 1.5h initial adhesion,
the medium was aspirated, and nonadhered cells were
removed and washed with sterile distilled water. RPMI 1640
medium was added to the adhered cells in the wells. The
plates were incubated for 24h at 37◦C[ 25].
2.8. Activity of the Essential Oil and Fractions from C. sativum
on the Bioﬁlm Formation in C. albicans. To evaluate the
antimicrobial activity of C. sativum essential oil on C.
albicans bioﬁlm formation, the samples were applied at
regular intervals during 24h at two diﬀerent concentra-
tions, corresponding to the MIC previously found for the
planktonic cells, and 1mg/mL. The applications were carried
out before planktonic cells adhesion (T0), after preadhesion
(T3 h )a n da f t e r6 h ,1 2 h ,1 8 h ,2 4 h ,a n d4 8 h .T h ep l a t e s
werereadatthefollowingintervalafterapplication.Thecon-
trols ﬂuconazole (fungistatic)—0064mg/mL and nystatin
(fungicidal)—1mg/mL were also included in the tests. The
testswereperformedinthreeindependentexperiments,each
in triplicate [25].
2.9. Bioﬁlm Quantiﬁcation. The bioﬁlm developed in each
well was washed twice with 200μL of distilled water and
then dried for 45min. In each well, 110μL of 0.4% crystal
violet were added for 45min. After this procedure, the wells
were washed four times with distilled water and immediately
discolored with 350μL of 95% ethanol. Elapsed 45 minutes
after the last procedure, 100μL of discolored solution was
transferred to a well of a new plate and the crystal violet
measured at 595nm in an ELISA reader (SpectraMax 340
tunable MICROPLATES Reader, Molecular Devices Ltda).
The amount of bioﬁlm formed was measured, subtracting
the absorbance from the absorbance values of the control
wells [26].
2.10. Scanning Electron Microscopy (SEM). I no r d e rt oe v a l -
uate C. albicans integrity cells using SEM, the bioﬁlms were
ﬁrst developed in Lab-Tek chambered coverglass (Nunc), as
describedabove,andtreatedwithC.sativumessentialoiland
standard drugs. The samples were ﬁxed in glutaraldehyde
0.15M 2.5% (v/v) PBS for one hour at room temperature.
After this procedure, the chambered coverglasses were
treated with 1% osmium trioxide for one hour and washed
three times with 3mL of distilled water. The chambered
coverglasses were then hydrated with an ethanol series (50%
to 100%), dried to a critical point and coated with gold in
the metalizer, and then observed using a scanning electron
microscope [27].
2.11. Gas Chromatography and Mass Spectrometry Analyses
(GC-MS). The identiﬁcation of volatile constituents was
performed using a Hewlett-Packard 6890 gas chromato-
graph, equipped with an HP-5975 mass selective detec-
tor and HP-5 capillary column (25m×0.25mm×0.25μm
diameter). GC and GC-MS were performed using split/
splitless injection, with the injector set at 220◦C, column
set at 60◦C, with a heating ramp of 3◦Cmin −1 and a ﬁnal
temperature of 240◦C, and the MS and FID detector set
at 250◦C. Helium was used as a carrier gas at 1mLmin−1.
The GC-MS electron ionization system was set at 70eV. A
sample of the essential oil was solubilized in ethyl acetate
for the analyses. Retention indices (RIs) were determined by
coinjection of hydrocarbon standards. The oil components
were identiﬁed by comparison with data from the literature,
the proﬁles, the Nist 05 library, and by co-injection of
authentic standards, when available [28].
2.12. Statistical Analysis. All statistical tests were performed
with one-way ANOVA, and P value of <. 05 was considered
statically signiﬁcant. The statistical test was run using STA-
TISTICA v.5.0 (Stasoft, USA) system software, and graphics
were carried out using SIGMAPLOT v.10.0. System software
(SPSS Inc.). Diﬀerent treatments were compared at all times
during the bioﬁlm assay.
3. Results
3.1. Oil and Extracts Yields. Oil and extracts yields were
expressed in relation to dry weight of the plant material (%
w/w). Larger quantities of essential oil were obtained from
C. martinii (1.36%) and C. winterianus (1.88%) followed
by S. chamaecyparissus (0.15%), C. sativum (0.08%), and
A. tuberosum (0.11%). Compared to essential oils, extract
yields were higher and ranged from 1,33% (C. sativum)t o
18.5% (A. tuberosum). The intermediate yields were 7.33%
(C. martini), 10.14% (S. chamaecyparissus), and 14.68%
(C. winterianus).
According to the activity results, the C. sativum essential
oil was fractioned in a dry column and the fractions grouped
according to the equivalence of the bands presented in thin
layer chromatography (TLC) analysis. The grouped F8–10
fractions presented the highest yield (155.20mg/g) followed
by F7 fraction (120.40mg/g), F5 fraction (25.90mg/g), F6
(22.60mg/g), and F3-4 grouped fraction (8.74m/g).
3.2. Essential Oil and Extract Activity against Planktonic
Candida spp. Minimum inhibitory concentration (MIC) of
the essential oils (EOs), dichloromethanic extracts (DEs),
and hexanic extract (HE) were tested against Candida spp.
planktonic cells, as indicated in Table 1. In general, the oils
and extracts presented a good action against planktonic
Candida spp. and clinical isolates; however, the oil and the
hexanic extract from C. sativum were capable of inhibiting4 Evidence-Based Complementary and Alternative Medicine
Table 1: Anti-Candida activity (MIC-mg/mL) of the essential oils, the dichloromethane (DE) and hexane (HE) extracts from the medicinal
species studied.
Candida spp. A. tuberosum C. sativum C. martinii C. winterianus S. chamaecyparissus
EO DE EO HE EO DE EO DE EO DE
Culture collection
C. albicans CBS 562 0.500 0.500 0.015 0.125 0.063 0.250 1.000 0.125 1.000 0.250
C. krusei CBS 573 >1.0 >1.0 0.015 0.125 0.063 0.125 0.063 0.063 0.500 0.500
C. parapsilosis CBS 604 0.015 0.015 0.125 0.031 0.125 0.063 1.000 0.125 1.000 1.000
C. dubliniensis CBS 7987 1.000 >1.0 0.007 0.031 0.125 0.250 0.500 0.125 0.063 0.063
C. tropicalis CBS 94 >1.0 >1.0 0.125 0.500 1.000 1.000 1.000 1.000 1.000 1.000
Clinical isolatesa
C. albicans 3 A5 0.500 >1.0 0.015 1.000 0.250 1.000 1.000 1.000 1.000 >1.0
C. albicans 13 A5 0.500 >1.0 0.031 1.000 0.063 1.000 0.500 1.000 1.000 >1.0
C. albicans 41 M2 0.500 >1.0 0.031 1.000 0.063 1.000 1.000 1.000 1.000 >1.0
C. albicans 50 M2 0.500 >1.0 0.063 1.000 0.250 1.000 0.500 1.000 1.000 >1.0
C. krusei 56 M3 0.007 >1.0 0.007 0.031 0.007 0.063 0.031 0.002 0.125 0.063
C. krusei 56 M4 1.000 >1.0 0.007 0.015 0.007 0.007 0.007 0.007 0.007 0.500
C. krusei 56 M6 1.000 >1.0 0.007 0.002 0.007 0.007 0.007 0.007 0.007 0.015
C. parapsilosis 45 M2 0.015 >1.0 0.007 0.063 0.031 0.063 0.250 0.250 0.500 0.125
C. parapsilosis 45 M4 0.015 >1.0 0.007 0.125 0.015 0.031 0.063 0.063 0.250 0.125
C. parapsilosis 45 M5 0.015 >1.0 0.015 0.007 0.250 1.000 1.000 0.063 1.000 1.000
C. dubliniensis 26 A2 1.000 >1.0 0.063 0.250 0.250 0.500 1.000 0.500 0.500 0.500
C. dubliniensis 26 A3 1.000 >1.0 0.031 0.250 0.250 0.500 1.000 0.250 0.250 0.500
C. dubliniensis 26 A4 >1.0 >1.0 0.500 0.250 1.000 0.250 1.000 0.250 0.500 1.000
C. tropicalis 53 M6 >1.0 >1.0 0.125 0.500 >1.0 >1.0 >1.0 >1.0 1.000 1.000
C. tropicalis 53 M7 >1.0 >1.0 0.063 0.250 0.250 0.250 1.000 1.000 >1.0 >1.0
C. tropicalis 53 M8 >1.0 >1.0 0.031 0.250 >1.0 >1.0 >1.0 >1.0 >1.0 >1.0
aThe codes correspond to the number of the volunteers and the place of sample origin; (A)-periodontal pocket; (M) oral mucosa.
Table 2: Anti-Candida activity (MIC-mg/mL) of crude essential oil (EO) and C. sativum fractions (F).
Candida spp. EO F3–F4 F5 F6 F7 F8–F10
Culture collection
C. albicans CBS 562 0.015 0.063 >1.0 0.500 0.125 0.015
C. krusei CBS 57 0.015 0.500 0.500 0.250 0.125 0.063
C. parapsilosis CBS 604 0.125 0.500 >1.0 0.250 0.250 0.063
C. dubliniensis CBS 7987 0.007 0.125 >1.0 0.063 0.063 0.031
C. tropicalis CBS 94 0.125 0.500 >1.0 1.000 0.063 0.063
Clinical isolatesa
C. albicans 13 A5 0.031 0.125 >1.0 0.500 0.250 0.063
C. krusei 56 M3 0.007 0.250 0.250 0.250 0.125 0.063
C. parapsilosis 45 M4 0.007 0.500 >1.0 0.250 0.250 0.063
C. dubliniensis 26 A3 0.031 0.250 >1.0 0.250 0.125 0.063
C. tropicalis 53 M7 0.063 >1.0 >1.0 1.000 0.250 0.125
aThe codes correspond to the number of the volunteers and the place of sample origin; (A)-periodontal pocket; (M) oral mucosa.
all strains at MIC values between 0.015–0.500mg/mL and
0.007–1.000mg/mL.
The activity of the fractions of C. sativum essential oil
was also tested against the planktonic cells of Candida spp.,
presenting in general strong activity, except for fraction 5
(Table 2). The lowest activity was observed for grouped F8–10
MIC value, the most polar fraction found by TLC analysis.
In order to compare the results of inhibition obtained from
the medicinal plants, two commercially available antifungal
agents were chosen: nystatin (polienic fungicide) and ﬂu-
conazole (azole fungistatic).
3.3. C. sativum Essential Oil Activity against C. albicans
Bioﬁlm. Figure 1(a) shows the kinetic bioﬁlm development
for C. albicans CBS 562 and clinical isolate 13A5. The action
of nystatin, ﬂuconazole, and C. sativum essential oil uponEvidence-Based Complementary and Alternative Medicine 5
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Figure 1: Bioﬁlm kinetic development: (a) Control, without treatment; (b) action of nystatin, ﬂuconazole and C. sativum essential oil in the
bioﬁlm kinetic development for C. albicans CBS 562; (c) action of nystatin, ﬂuconazole and C. sativum essential oil in the bioﬁlm kinetic
development for C. albicans clinical isolate 13A5.
bioﬁlm growth was presented in Figures 1(b) and 1(c).T h e
crude essential oil from C. sativum and drugs was applied
at regular intervals during bioﬁlm cultivation. The results
showninFigures1(b)and1(c)indicateacleareﬀectoftheoil
on bioﬁlm formation, characterized due to an increase in the
lagphaseandadecreaseinthebioﬁlmgrowth.Similareﬀects
were observed for nistatin, though inferior to ﬂuconazole
(P ≤ .05).
The statistical analysis demonstrated a signiﬁcative
diﬀerence (P ≤ .05) after 48h of treatment (Figures 1(b),
1(c)). Considering the results obtained for C. albicans
CBS 562, the best treatments were nystatin (1mg/mL) and
essential oil (0.125mg/mL). For the clinical isolate 13A5,
the eﬀect on the bioﬁlm was statistically identical as that
for nystatin (1mg/mL), ﬂuconazole (0.0641mg/mL), and
essential oil (1mg/mL), though inferior for the essential oil
at 0.125mg/mL.
3.4. Chemical Characterization of Oil Constituents. The
chemical composition of the essential oil and grouped F8–10
fractionsfromC.sativumisshowninTable 3.Theevaluation
wasperformedbygaschromatographycoupledtomassspec-
trometry (GC-MS). The oil analysis indicated the presence
of volatile derivatives of alcohols and aldehydes, such as
decene, decanal, decenol, decenal, decanol, dodecanal, dode-
canol, tetradecenal, tetradecanol, tridecanol, hexenol, and
cyclodecane. Fraction F8–10 was enriched with 3-hexen-1-ol
(16.08%), 2-hexen-1-ol (14.52%), and 1-decanol (44.16%).
Further experiments were carried out aiming to evaluate the
actionoftheisolatedcomponents(Sigma-Aldrichstandards)
against C. albicans planktonic cells (Table 4).
3.5. Scanning Electron Microscopy. The action of C. sativum
crude oil and grouped F8–10 fractions upon C. albicans cells
and bioﬁlm morphology, evaluated by scanning electron
microscopy (SEM), is presented in Figures 2(a)–2(c) and
demonstrates that the plant materials caused an amendment
in cell structure.
4. Discussion
The activity of natural products upon microorganisms
has been recently conﬁrmed by literature. Plant materials6 Evidence-Based Complementary and Alternative Medicine
Table 3: Identiﬁed compounds, retention time (Rt), retention Index (RI), and relative percentage (%) in crude oil and C. sativum essential
oil fractions F8–10.
Rt (min) RI Compounds %R e l a t i v e
Crude oil F8–10
3.54 — 3-hexen-1-ol <E> —0 . 4 4
3.63 — 3-hexen-1-ol <Z> 1.24 16.08
3.78 — 2-hexen-1-ol <Z> 0.77 14.52
5.19 933 α-pinene 0.15 —
10.23 1101 Undecane 0.33 —
10.40 1106 Nonanal 0.28 —
13.02 1172 Nonanol 0.19 —
14.49 1209 Decanal 10.97 —
16.73 1262 2-decenal <E> 2.74 —
17.12 1272 2-decen-1-ol <E> 4.11 —
17.32 1277 1-decanol 15.30 44.16
18.65 1309 Undecanal 2.20 —
20.96 1364 2-undecenal <E> 1.01 —
21.25 1371 2-undecenol <E> 1.21 1.71
21.38 1375 Undecanol 1.96 3.62
22.89 1411 dodecanal 7.53 —
25.19 1469 2-dodecenal 8.16 —
25.45 1475 2-dodecenol 11.26 13.04
25.52 1477 Cyclododecane 2.54 4.43
26.89 1512 Tridecanal 1.00 —
29.11 1570 2-tridecenal <E> 1.44 —
29.28 1574 2-tridecenol <E> 0.86 —
29.56 1581 Caryophyllene oxide 0.47 —
30.78 1614 Tetradecanal 1.26 —
33.01 1674 2-tetradecenol <E> 13.58 —
36.58 1775 2-pentadecenol 3.10 —
40.03 1879 2-hexadecenol 0.80 —
47.73 — Phytol 3.06 —
— — nonidentiﬁed compounds 2.52 2.01
Table 4: Anti-Candida activity (MIC-mg/mL) of the C. sativum essential oil (OE), fractions F8–10 and from the major compounds present
in F8–10.
Candida spp. EO Fractions F8–10 2 -hexen-ol cis 2-hexen-ol trans 3-hexen-ol cis 3-hexen-ol trans 1-decanol
Majority
compounds
mixture
C. albicans CBS 562 0.015 0.015 0.063 0.031 0.500 0.063 0.031 0.0005
C. albicans 13 A 0.031 0.063 0.063 0.007 0.125 0.031 0.015 0.0005
such as extracts, essential oils, and isolated compounds
have demonstrated inhibition against bacteria [29], yeast
[30], and ﬁlamentous fungi [31]. Most studies, however,
focus on planktonic cells; nevertheless, the fact that several
microorganisms are capable of growing as a bioﬁlm, leading
to a greater resistance to drugs, indicates the need for further
activitystudieswiththesenaturalproductsregardingbioﬁlm
mechanismformation.Inthepresentstudy,essentialoilsand
extracts from 5 diﬀerent medicinal species, with previously
known antimicrobial activity [30, 32, 33], were evaluated
against Candida spp. planktonic cells and C. albicans bioﬁlm.
As there is no consensus regarding the acceptable
inhibition level for natural products when compared with
standard antibiotics, we have considered the deﬁnition
proposed by Duarte et al. [30], being strong activity-MIC
up to 0.5mg/mL; moderate activity-MIC between 0.51 and
1.0mg/mL, and weak activity-MIC above 1.1mg/mL. Thus,
the results obtained in the present work show a broad action
of oils and extracts, with a greater activity for essential
oils than for extracts, capable of inhibiting the diﬀerent
Candida spp. CBS and clinical isolates with moderate to
strong activity. When the plant materials were comparedEvidence-Based Complementary and Alternative Medicine 7
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Figure 2: Scanning electron microscopy (SEM) of the C. albicans bioﬁlm: (a) without treatment; (b) treated with C. sativum crude essential
oil; (c) treated with grouped fractions F8–10.
with ﬂuconazole and nystatin activity, the plant materials
weresimilarorbetterthantheaforementioneddrugsinsome
cases.
Considering the susceptibility of CBS standard strains
and the clinical isolates, the strains from CBS collection
were, in general, more sensitive to essential oils. Among
the diﬀerent species investigated, clinical isolates from C.
dubliniensis and C. tropicalis were the most resistant species
(moderate to weak activities—MIC ≥ 1.0mg/mL), except in
the case of the essential oil from C. sativum.
The oil from C. sativum, ap l a n tu s e da sav e r yc o m m o n
condiment in Brazilian Northeast food, was capable of
inhibiting all Candida spp. CBS and clinical isolates in the
initial assays. The fractionation of the oil emphasized F8–10
fraction activity; however, the application in planktonic cells
did not incur in the best activities, indicating the potential
use of this plant in the form of crude oil. F8–10 fractions
presented as main constituents 2-hexen-ol, 3-hexen-ol, and
1-decanol, and when tested alone or grouped showed a
synergistic action from the compounds, as the mixture
presented the lowest MIC values.
The crude essential oil from C. sativum applied at regular
intervals aﬀected bioﬁlm development and caused a delay
in the lag phase and a decrease in the bioﬁlm growth8 Evidence-Based Complementary and Alternative Medicine
(Figures 1(b) and 1(c)) when compared to the control assay
(Figure 1(a)). The response of C. albicans CBS 562 and
clinical isolate 13A5 to treatments was diﬀerent, as this last
presented a higher growth in the presence of the drugs
and essential oil. The statistical analysis demonstrated a
signiﬁcative diﬀerence (P ≤ .05) after 48h of treatment,
showing a similar action for nystatin and C. sativum essential
oil. The activity of the materials tested in the present study
was conﬁrmed through SEM analysis and demonstrated cell
deformation, presenting a withered appearance.
5. Conclusion
In conclusion, the results of the present study indicate the
potential use of themedicinal species for oral candidosis
prevention or treatment and emphasize the action of the
crude C. sativum essential oil, which demonstrates a strong
activity against Candida spp. planktonic cells and C. albicans
bioﬁlm.
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